Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients

Respiratory Physiology and Neurobiology

Volumn 197, Issue 1, 2014, Pages 36-45

  Santus, Pierachille ^a   Radovanovic, Dejan ^a   Henchi, Sonia ^a   Di Marco, Fabiano ^a   Centanni, Stefano ^a   D'Angelo, Edgardo ^a   Pecchiari, Matteo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Adrenergic beta agonists; Dyspnea; Plethysmography; Respiratory function tests; Reversibility; Short term variability

Indexed keywords

INDACATEROL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

AGED; AIRWAY RESISTANCE; ARTICLE; BREATHING RATE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RESIDUAL VOLUME; TOTAL LUNG CAPACITY; VISUAL ANALOG SCALE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ADRENERGIC BETA-AGONISTS; AGED; AIRWAY RESISTANCE; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSPNEA; FEMALE; HUMANS; INDANS; LUNG VOLUME MEASUREMENTS; MALE; PLETHYSMOGRAPHY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RESPIRATORY FUNCTION TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901238766     PISSN: 15699048     EISSN: 18781519     Source Type: Journal    
DOI: 10.1016/j.resp.2014.03.012     Document Type: Article

References (36)

1. American Thoracic Society Dyspnea. Mechanisms, assessment, and management: a consensus statement. Am. J. Respir. Crit. Care Med. 1999, 159:321-340.
2. Barnes P.J., Gribbin H.R., Osmanliev D., Pride N.B. Partial flow-volume curves to measure bronchodilator dose-response curves in normal humans. J. Appl. Physiol. 1981, 50:1193-1197.
3. Bassiri A.G., Girgis R.E., Doyle R.L., Theodore J. Detection of small airway dysfunction using specific airway conductance. Chest 1997, 111:1533-1535.
4. Beier J., Beeh K-M., Brookman L., Peachey G., Hmissi A., Pascoe S. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm. Pharmacol. Therap. 2009, 22:492-496.
5. Berry R.B., Fairshter R.D. Partial and maximal expiratory flow-volume curves in normal and asthmatic subjects before and after inhalation of metaproterenol. Chest 1985, 88:697-702.
6. Borrill Z.L., Houghton C.M., Woodcock A.A., Vestbo J., Singh D. Measuring bronchodilation in COPD clinical trials. Br. J. Clin. Pharmacol. 2004, 59:379-384.
7. Deesomchok A., Webb K.A., Forkert L., Lam Y.M., Ofir D., Jensen D., O'Donnell D. Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. COPD 2010, 7:428-437.
8. D'Angelo E., Pecchiari M., Saetta M., Balestro E., Milic-Emili J. Dependence of lung injury on inflation rate during low-volume ventilation in normal open-chest rabbits. J. Appl. Physiol. 2004, 97:260-268.
9. D'Angelo E., Koutsoukou A., Della Valle P., Gentile G., Pecchiari M. Cytokine release, small airway injury, and parenchymal damage during mechanical ventilation in normal open-chest rats. J. Appl. Physiol. 2008, 104:41-49.
10. Di Marco F., Milic-Emili J., Boveri B., Carlucci P., Santus P., Casanova F., Cazzola M., Centanni S. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur. Respir. J. 2003, 21:86-94.
11. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease updated 2013. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf.
12. Guidance for Industry Chronic obstructive pulmonary disease: developing drugs for treatment. US Department of Health and Human Services Food and Drug Administration Center 2007, http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/ucm071575.pdf. Published November 2007 (accessed 11.10.13).
13. Hanania N.A., Celli B.R., Donohue J.F., Martin U.J. Bronchodilator reversibility in COPD. Chest 2011, 140:1055-1063.
14. Mahut B., Caumont-Prim A., Plantier L., Gillet-Juvin K., Callens E., Sanchez O., Chevalier-Bidaud B., Bokov P., Delclaux C. Relationships between respiratory and airway resistances and activity-related dyspnea in patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2012, 7:165-171.
15. Newton M.F., O'Donnell D.E., Fokert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002, 121:1042-1050.
16. Noseda A., Schmerber J., Prigogine T., Yernault J.C. How do patients with either asthma or COPD perceive acute bronchodilation. Eur. Respir. J. 1993, 6:636-644.
17. Nucci G., Suki B., Lutchen K. Modelling airflow-related shear stress during heterogeneous constriction and mechanical ventilation. J. Appl. Physiol. 2003, 95:348-356.
18. Pellegrino R., Rodarte J.R., Brusasco V. Assessing the reversibility of airway obstruction. Chest 1998, 114:1607-1612.
19. Pellegrino R., Viegi G., Brusasco V., Crapo R.O., Burgos F., Casaburi R., Coates A., van der Grinten C.P.M., Gustafsson P., Hankinson J., Jensen R., Johson D.C., MacIntyre N., McKay R., Miller M.R., Navajas D., Pedersen O.F., Wanger J. ATS/ERS task force: standardization of lung function testing. Interpretative strategies for lung function tests. Eur. Respir. J. 2005, 26:948-968.
20. Pride N.B. The assessment of airflow obstruction: role of measurements of airway resistance and of tests of forced expiration. Br. J. Dis. Chest 1971, 65:135-169.
21. Quanjer P.H. Standardized lung function testing. Bull. Eur. Physiopathol. Respir. 1983, 19(suppl. 5):22-61.
22. Ramsdell J.W., Tisi G.M. Determination of bronchodilation in the clinical pulmonary function laboratory. Chest 1979, 76:622-628.
23. Rennard S., Bantje T., Centanni S., Chanez P., Chuchalin A., D'Urzo A., Kornmann O., Perry S., Jack D., Owen R., Higgins M. A dose-ranging study of indacaterol in obstructive airways disease, with tiotropium comparison. Respir. Med. 2008, 102:1033-1044.
24. Ries A.L. Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD 2005, 2:105-110.
25. Ries A.L. Impact of chronic pulmonary disease on quality of life: the role of dyspnea. Am. J. Med. 2006, 119:512-520.
26. Rossi A., Centanni S., Cerveri I., Gulotta C., Foresi A., Cazzola M., Brusasco V. Acute effects of indacaterol on lung hyprinflation in moderate COPD: a comparison with tiotropium. Respir. Med. 2012, 106:84-90.
27. Schermer T., Heijdra Y., Zadel S., van den Bemt L., Boonman-de Winter L., Dekhuijzen R., Smeele I. Flow and volume responses after routine salbutamol reversibility testing in mild to severe COPD. Respir. Med. 2007, 101:1355-1362.
28. Skinner C., Palmer K.N.V. Changes in specific airway conductance and forced expiratory volume in one second after a bronchodilator in normal subjects and patients with airway obstruction. Thorax 1974, 29:574-577.
29. Smith H.R., Irvin C.G., Cherniack R.M. The utility of spirometry in the diagnosis of reversible airway obstruction. Chest 1992, 101:1577-1581.
30. Sourk R.L., Nugent K.M. Bronchodilator testing: confidence intervals derived from placebo inhalation. Am. Rev. Respir. Dis. 1983, 128:153-157.
31. Taskin D.P., Celli B., Decramer M., Liu D., Burkhart D., Cassino C., Kesten S. Bronchodilator responsiveness in patients with COPD. Eur. Respir. J. 2008, 31:742-750.
32. Taube C., Lehnigk B., Paasch K., Kirsten D.K., Jörres R.A., Magnussen H. Factor analysis of changes in dyspnea and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000, 162:216-220.
33. Vogelmeier C., Ramos-Barbon D., Jack D., Piggott S., Owen R., Higgins M., Kramer B. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir. Res. 2010, 11:135.
34. Wanger J., Clausen J.L., Coates A., Pedersen O.F., Brusasco V., Burgos F., Casaburi R., Crapo R.O., Enright P., van der Grinten C.P.M., Gustafsson P., Hankinson J., Jensen R., Johson D., MacIntyre N., McKay R., Miller M.R., Navajas D., Pellegrino R., Viegi G. ATS/ERS task force: standardization of lung function testing. Standardization of the measurement of lung volumes. Eur. Respir. J. 2005, 26:511-522.
35. Widdicombe J.H., Widdicombe J.G. Regulation of human airway surface liquid. Respir. Physiol. 1995, 99:3-12.
36. Wolkove N., Dajczman E., Colacone A., Kreisman H. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest 1989, 96:1247-1251.